Crossmark

: S.A. received honoraria for consulting from Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Novartis, Satsuma, Supernus, Theranica and Percept. S.A. is an associate editor for Neurology Reviews and BMC Neurology, serves on an Advisory Board for the Journal of Headache and Pain, and is a member of the Education Committee of the International Headache Society. D.D.M. has received honoraria as a consultant and/or speaker from Allergan/AbbVie, Amgen, Biogen, Cefaly, Eli Lilly, Genesis Pharma, Medscape, Merz, Mylan, Novartis, Roche, Sanofi, Specifar and Teva Pharmaceuticals; has received funding for clinical trials from Alder, Cefaly, Electrocore, Biogen, Eli Lilly, Genesis Pharma, Merz, Novartis and Teva. D.D.M. is also past president of the European Headache Federation, current co-chair of the Headache Panel in the European Academy of Neurology and president of the Hellenic Headache Society, and is an associate editor for Journal of Headache and Pain. D.D.M. does not own stocks from any pharmaceutical company. M.J.L. has received honoraria as a consultant and/or speaker for Eli Lilly, Sanofi-Aventis and YuYu Pharma; has been the PI or co-investigator in trials sponsored by Eli Lilly, Novartis, Teva (Otsuka), Allergan/AbbVie, Yuhan Company, Samjin Pharm and DongA ST; received research support from the National Research Foundation of Korea; is a trustee member of the board of the International Headache Society and junior editor of Cephalalgia. S-J.W. has served on the advisory boards of Daiichi-Sankyo, Eli Lilly and Taiwan Novartis; has received honoraria as a moderator from Allergan/AbbVie, Pfizer, Eli Lilly and Eisai and has been the PI in trials sponsored by Eli Lilly, Novartis, and Allergan/AbbVie. S-J.W. has received research grants from the Taiwan Minister of Technology and Science (MOST), Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Taipei Veterans General Hospital and Taiwan Headache Society. R.M. has received honoraria as speaker for Eli Lilly, Novartis and Teva Pharmaceuticals. D.B. received honoraria for consulting for Allergan, Amgen, Biohaven, Eli Lilly, Novartis and Teva, and has received grant support from Amgen, the National Headache Foundation and the FDA. D.B. is an editor for Current Pain and Headache Reports. P.P.-R. has received honoraria as a consultant and/or speaker for Allergan/AbbVie, Almirall, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Neurodiem, Novartis and Teva Pharmaceuticals. Her research group has received research grants from AGAUR, ERANet Neuron, la Caixa foundation, International Headache Society, Migraine Research Foundation, FEDER RISC3CAT, Instituto Investigación Carlos III, PERIS, Novartis and Teva; and has received funding for clinical trials from AbbVie, Alder, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva. P.P.-R. is a trustee member of the board of the International Headache Society and a member of the Council of the European Headache Federation, and is on the editorial board of Revista de Neurologia; is an associate editor for Cephalalgia, Headache, Frontiers in Neurology, Neurologia and is on the Scientific Advisory Board of the Journal of Headache and Pain. P.P.-R. does not own stocks from any pharmaceutical company. R.H.J. has received honoraria for lectures and patient leaflets from MSD, Berlin-Chemie Menarini, ATI, Novartis, Teva, Allergan and Pfizer and is conducting clinical trials for Eli-Lilly and Lundbeck. H.-C.D. received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Allergan/AbbVie, Amgen, Electrocore, Lilly, Medtronic, Novartis, Pfizer, Teva and Weber & Weber. Electrocore provided financial support for research projects. The German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union support his headache research. H.-C.D. serves on the editorial boards of Cephalalgia and Lancet Neurology, chairs the Clinical Guidelines Committee of the German Society of Neurology and is a member of the Clinical Trials Committee of the IHS. R.B.L. is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH. R.B.L. also receives support from the Migraine Research Foundation and the National Headache Foundation. R.B.L. serves on the editorial board of Neurology, is senior adviser to Headache, associate editor for Cephalalgia and has reviewed for the NIA and NINDS, holds stock options in Biohaven Holdings and CntrlM; serves as consultant, advisory board member, or has received honoraria or conducted research funded by Allergan/Abbvie, American Academy of Neurology, American Headache Society, Amgen, Biohaven, Biovision, Dr. Reddy’s (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Teva, Trigemina, Vector, Vedanta. R.L. receives royalties from Wolff’s Headache seventh and eighth editions, Oxford University Press, 2009, Wiley and Informa. All other authors declare no competing interests.

Document is current

Any future updates will be listed below